ParkinsonCanadaV1, PubMed, Curation, bibRecord, 001377

Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.

Identifieur interne : 001377 ( PubMed/Curation ); précédent : 001376; suivant : 001378

Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.

Auteurs : Yoshiaki Furukawa [Canada]

Source :

Advances in neurology [ 0091-3952 ] ; 2004.

RBID : pubmed:14509665

English descriptors

KwdEn :
- Antiparkinson Agents (therapeutic use), Brain Chemistry, Dystonia (classification), Dystonia (complications), Dystonia (drug therapy), Dystonia (genetics), Family Health, GTP Cyclohydrolase (deficiency), GTP Cyclohydrolase (genetics), Genetic Heterogeneity, Genetic Linkage, Humans, Levodopa (therapeutic use), Motor Activity, Mutation, Parkinson Disease, Secondary (complications), Parkinson Disease, Secondary (genetics), Phenylketonurias (etiology), Phenylketonurias (genetics), Tyrosine 3-Monooxygenase (genetics).
MESH :
- chemical , deficiency : GTP Cyclohydrolase.
- chemical , genetics : GTP Cyclohydrolase, Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- classification : Dystonia.
- complications : Dystonia, Parkinson Disease, Secondary.
- drug therapy : Dystonia.
- etiology : Phenylketonurias.
- genetics : Dystonia, Parkinson Disease, Secondary, Phenylketonurias.
- Brain Chemistry, Family Health, Genetic Heterogeneity, Genetic Linkage, Humans, Motor Activity, Mutation.

PubMed: 14509665

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001377

Links to Exploration step

pubmed:14509665

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.</title>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:14509665</idno>
<idno type="pmid">14509665</idno>
<idno type="wicri:Area/PubMed/Corpus">001377</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001377</idno>
<idno type="wicri:Area/PubMed/Curation">001377</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001377</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.</title>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Advances in neurology</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Brain Chemistry</term>
<term>Dystonia (classification)</term>
<term>Dystonia (complications)</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (genetics)</term>
<term>Family Health</term>
<term>GTP Cyclohydrolase (deficiency)</term>
<term>GTP Cyclohydrolase (genetics)</term>
<term>Genetic Heterogeneity</term>
<term>Genetic Linkage</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Motor Activity</term>
<term>Mutation</term>
<term>Parkinson Disease, Secondary (complications)</term>
<term>Parkinson Disease, Secondary (genetics)</term>
<term>Phenylketonurias (etiology)</term>
<term>Phenylketonurias (genetics)</term>
<term>Tyrosine 3-Monooxygenase (genetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>GTP Cyclohydrolase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>GTP Cyclohydrolase</term>
<term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dystonia</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Phenylketonurias</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Dystonia</term>
<term>Parkinson Disease, Secondary</term>
<term>Phenylketonurias</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Brain Chemistry</term>
<term>Family Health</term>
<term>Genetic Heterogeneity</term>
<term>Genetic Linkage</term>
<term>Humans</term>
<term>Motor Activity</term>
<term>Mutation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14509665</PMID>
<DateCreated><Year>2003</Year>
<Month>09</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>10</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-3952</ISSN>
<JournalIssue CitedMedium="Print"><Volume>94</Volume>
<PubDate><Year>2004</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurology</Title>
<ISOAbbreviation>Adv Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.</ArticleTitle>
<Pagination><MedlinePgn>127-38</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furukawa</LastName>
<ForeName>Yoshiaki</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Neurol</MedlineTA>
<NlmUniqueID>0367524</NlmUniqueID>
<ISSNLinking>0091-3952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber>
<NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.5.4.16</RegistryNumber>
<NameOfSubstance UI="D006136">GTP Cyclohydrolase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006136" MajorTopicYN="N">GTP Cyclohydrolase</DescriptorName>
<QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018740" MajorTopicYN="Y">Genetic Heterogeneity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010661" MajorTopicYN="N">Phenylketonurias</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>108</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>10</Month>
<Day>24</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14509665</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001377 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001377 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:14509665
   |texte=   Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:14509665" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.

Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki